Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | LGMN | Q99538 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23293400 | 0.86 | GPR119 (0.45) | MAPTLGMNALDH1A1HSP90AA1MAPK1 | |
| SCHEMBL25030014 | 0.86 | MAPT (0.57) | MAPTALDH1A1KDM4EPDK2GPR119 | |
| SCHEMBL2302426 | 0.84 | HPGD (0.54) | MAPTALDH1A1HSP90AA1MAPK1HTT | |
| SCHEMBL1666181 | 0.84 | TSHR (0.57) | MAPTLGMNALDH1A1HTTKDM4E | |
| SCHEMBL1665448 | 0.83 | MAPT (0.67) | MAPTLGMNALDH1A1HSP90AA1MAPK1 | |
| SCHEMBL21679219 | 0.83 | GPR119 (0.53) | ALDH1A1GPR119 | |
| SCHEMBL30378807 | 0.83 | LGMN (0.54) | MAPTLGMNALDH1A1HTTKDM4E | |
| SCHEMBL26090350 | 0.83 | LGMN (0.54) | MAPTLGMNALDH1A1HTTKDM4E | |
| SCHEMBL1665672 | 0.83 | MAPT (0.53) | MAPTLGMNALDH1A1MAPK1HTT | |
| SCHEMBL22444292 | 0.82 | MAPT (0.65) | MAPTLGMNALDH1A1HSP90AA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| EP-3814326-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513017-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 爱尔兰詹森科学公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-111718293-A | Process for producing bisarylamide derivative | 持田制药株式会社 | 2020-09-29 | — | — | CN | disclosed |
| WO-2020188833-A1 | MANUFACTURING METHOD FOR BIARYL AMIDE DERIVATIVE | 持田製薬株式会社 | 2020-09-24 | — | — | WO | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| WO-2019189766-A1 | NOVEL BIARYL AMIDE DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-5795893-A | Fibrinogen receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0801650-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0801650-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
| WO-1996019475-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | MAPT 4190/4885LGMN 1888/4885ALDH1A1 1223/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | MAPT 4307/4885LGMN 2999/4885ALDH1A1 1247/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | MAPT 4190/4885LGMN 1888/4885ALDH1A1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.